Meeting
2016 ASCO Annual Meeting
Frequency and risk factors for tyrosine kinase inhibitor–associated cardiotoxicity.
Authors
Peter J. Hurley
University of Minnesota, St Paul, MN
Peter J. Hurley , Suma Konety , Qing Cao , Charles Oertli , Srilakshmi Vankina , Anne Hudson Blaes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality of Care
Track
Health Services Research and Quality of Care
Sub Track
Safety and Quality of Care
Citation
J Clin Oncol 34, 2016 (suppl; abstr 6596)
DOI
10.1200/JCO.2016.34.15_suppl.6596
Abstract #
6596
Poster Bd #
82
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A retrospective natural history study of patients (pts) with PDGFRα D842V mutant advanced gastrointestinal stromal tumor (GIST) previously treated with a tyrosine kinase inhibitor (TKI).
First Author: Margaret von Mehren
Poster
2017 ASCO Annual Meeting
A randomized, double-blind, placebo-controlled, phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in PDGFRA: The CrenoGIST study.
First Author: Jean-Yves Blay
Poster
2023 ASCO Annual Meeting
Proposition of a drug score to predict the clinical usefulness of therapeutic dose monitoring of oral molecularly targeted therapies.
First Author: Arthur Geraud
Poster
2022 ASCO Annual Meeting
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
First Author: Steven Bialick